

5 challenges slowing drug development and how to overcome them

1

Patient recruitment

Patient recruitment remains one of the largest barriers to timely clinical trial completion, with 39% of drug developers naming it a significant challenge¹.



Solution: Partnering with an experienced CRO with a track record of low turnover can help fill talent gaps while ensuring high-quality trial execution, accelerating drug development timelines, and maintaining stability to preserve valuable study and scientific knowledge.


2

Trial complexity

Two in five drug developers say trial complexity is a top challenge impacting timelines and increasing costs¹.



Solution: Integrated solutions that combine CRO and CDMO services under one roof can mitigate risks and enhance collaboration, providing end-to-end coverage that simplifies trials and accelerates timelines.



3

Feasibility and site selection

One third of respondents reported feasibility and site selection as a hurdle impacting their timelines¹.



Solution: Streamlining feasibility questionnaires to focus on key questions and implementing an electronic confidentiality statement (e-CDS) can significantly reduce site selection timelines, cutting down weeks or even months from study startup.


4

Finding vendors with scientific/therapeutic expertise

More than a quarter of drug developers surveyed reported difficulty finding vendors with necessary scientific or therapeutic area expertise, which has negative impacts on their timelines¹.



Solution: Partnering with an experienced CRO with a track record of low turnover can help fill talent gaps while ensuring high-quality trial execution, accelerating drug development timelines, and maintaining stability to preserve valuable study and scientific knowledge.



5

Navigating changing regulatory landscape

One in five respondents reported navigating a changing regulatory landscape as a significant challenge impacting their timelines¹.



Solution: Choosing a regulatory partner with a proven track record of successful submissions in your therapeutic area can significantly mitigate risks and reduce time to market. Their expertise ensures compliance with evolving global standards and provides tailored strategies to navigate complex approval processes, accelerating drug development timelines.

It's difficult to accelerate trials in today's complex and competitive landscape but bringing therapies to market quickly is key to driving down cost, maximizing ROI, and serving patients quickly with the therapies they need most.

At the PPD™ clinical research business of Thermo Fisher Scientific, we work together to devise the transformative strategies that position you to meet key milestones, faster.

Our survey of 150 global drug developers revealed key obstacles that hinder timelines. With an experienced partner, you can overcome these challenges efficiently – staying on schedule and budget to deliver lifesaving treatments faster to those who need them most.

The time is now.

Ready to accelerate your discoveries?

Learn more at ppd.com/its-about-time/



Source:
[The Pulse: Global R&D Insights in Pharmaceuticals](#)